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Selective targeting of lysosomal cysteine proteases with
radiolabeled electrophilic substrate analogs
Matthew Bogyo1, Steven Verhelst2, Valerie Bellingard-Dubouchaud3, Sam Toba4
and Doron Greenbaum4
Background: The lysosomal cysteine proteases of the papain family are some
of the best studied proteolytic enzymes. Small-molecule inhibitors and
fluorogenic substrate mimics have been used to probe the physiological roles of
these proteases. A high degree of homology between family members and
overlap in substrate specificity have made elucidating individual protease
function, expression and activity difficult.
Results: Using peptide vinyl sulfones and epoxide as templates, we have
generated probes that can be tagged with radioactive iodine. The resulting
compounds covalently label various cathepsins and several unidentified
polypeptides likely to be proteases. MB-074 was found to be a highly selective
probe of cathepsin B activity. Probes that labeled several cathepsins were used
to examine the specificity and cell permeability of the CA-074 family of
inhibitors. Although CA-074 reportedly acts in vivo, we find it is unable to
penetrate cells. Esterifying CA-074 resulted in a cell-permeable inhibitor with
dramatically reduced activity and specificity for cathepsin B. The probes were
also used to monitor protease activity in primary human tumor tissue and cells
derived from human placenta. 
Conclusions: We have generated a highly selective cathepsin B probe and
several less specific reagents for the study of cathepsin biology. The reagents
have several advantages over commonly used fluorogenic substrates, allowing
inhibitor targets to be identified in a pool of total cellular enzymes. We have
used the probes to show that cathepsin activity is regulated in tumor tissues
and during differentiation of placental-derived cytotrophoblasts to invasive cells
required for establishing blood circulation in a developing embryo. 
Introduction
The lysosomal cathepsins are proteases with diverse func-
tions ranging from the generation of antigenic peptides to
the turnover of misfolded proteins (for reviews see [1,2]).
One of the largest subclasses of this family is a series of
papain-like proteases that utilize a catalytic cysteine for
proteolysis. Some of the most well known members of this
cysteine protease family include cathepsins B, L, H, S, N
and K. Much work has focused on these proteases and
their involvement in several disease states (for a compre-
hensive review see relevant chapters in [3]). 
Cathepsin B, in particular, has received much attention for
its potential role in conditions such as cancer (reviewed in
[4]), rheumatoid arthritis [5] and muscular dystrophy [6].
Most of these studies have focused on the development of
diagnostic techniques for monitoring levels of cathepsin B
expression using specific antibodies or by monitoring
levels of mRNA [4]. These methods have been used in
particular to examine the role of the lysosomal cathepsins
in tumor progression and metastasis. Although such
studies have established a connection between tumor
invasiveness and cathepsin expression, they provide little
information about actual levels of activity of individual
proteases. For this reason, reagents that correlate more
directly with activity could be a useful complement to the
established expression methods.
Currently, one of the few sensitive methods available to
monitor activity of proteases employs short peptides that
have been modified with a fluorogenic moiety, which,
when released by proteolysis, results in an easily detected
fluorescent by-product. These types of substrates are often
used in vitro to perform Michaelis–Menten kinetic analysis
when purified enzyme is available. Such reporter sub-
strates can also be used in zymograms to visualize protease
bands within a native-type gel. The ease of synthesis of
modified peptide fluorophores combined with information
from cellular protein substrates has led to the development
of substrates that are able to discriminate between often
closely related proteases. This discrimination is far from
absolute, however, and complications arise when substrate
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hydrolysis is measured in complex mixtures of proteins. In
addition, reactivity towards fluorogenic substrates can be
accurately assessed only for known enzymes and fails to
address other as-yet-unidentified proteases.
Some of the most commonly used tools to monitor cathep-
sin function are low molecular weight protease inhibitors
(for reviews see [7,8]). Like substrate analogs, these
reagents must be designed to accomplish the difficult task
of discriminating between closely related enzyme family
members. Selectivity has recently been achieved by
exploiting cathepsin B’s unique dipeptidyl peptidase activ-
ity. Compounds such as CA-074 (Figure 1) and CA-030 are
peptide epoxides containing a short dipeptide free-acid
that have been reported as specific cathepsin B inhibitors
[9,10]. Structural studies show that these compounds bind
with the peptide portion of the molecules, occupying the
enzyme’s S′ subsite, an orientation that is the inverse of
that observed for other epoxide-containing inhibitors of the
E-64 family [11]. Specificity for cathepsin B is achieved
through binding interactions between the free carboxylate
of proline and two highly conserved histidine residues from
the so-called ‘occluding loop’ that directs the di-peptidyl
peptidase activity unique to cathepsin B [12] facing the S′
substrate binding pocket (Figure 2). 
Several studies using CA-074 and CA-030 have been
reported since their initial synthesis [11,13–16]. Specificity
of these compounds for cathepsin B has only been
addressed using fluorogenic substrates in vitro with puri-
fied enzymes or with crude cellular mixtures [9,10]. These
types of studies, although informative, are plagued by the
lack of synthetic substrates capable of absolute discrimina-
tion between cathepsin B and other cysteine proteases of
the cathepsin and calpain family. In addition, no informa-
tion regarding the reactivity of CA-074 and analogs
towards unidentified proteases is available.
Effects of in vivo treatment of mice with CA-074 have
been reported and these results were interpreted as a
direct examination of the role of cathepsin B in antigen
presentation [14–16]. The presence of the charged car-
boxylic acid moiety required for cathepsin B specificity,
however, makes the cell permeability of this class of com-
pounds questionable. To increase membrane permeabil-
ity, an analog in which the proline free-acid group of
CA-074 was converted to its methyl ester was reported
[17]. This ester was shown to penetrate cells and to lead to
a reduction in cathepsin B activity as measured by hydroly-
sis of a fluorogenic substrate. Buttle and colleagues [17]
reason that although modification of the critical histidine-
binding carboxylic acid results in reduced potency and
specificity for cathepsin B, with time, nonspecific esterases
convert the ester form of the inhibitor to the active acid
form. The methyl ester CA-074-OMe has therefore been
suggested to be a specific pro-inhibitor of cathepsin B [17].
The natural product E-64 is a peptide epoxide that
inhibits most of the known lysosomal cysteine proteases
by covalently modifying their active-site nucleophiles [18]
(Figure 1). E-64 and related derivatives can be synthe-
sized using a short and direct route from readily available
diethyl tartrate. As a result, several analogs have been
reported in which modifications to the pseudo-peptide
portion of the molecule have been made [13,19,20]. In one
such compound, JPM-565 (Figure 1), the guanidinium-
containing arganine group has been replaced with tyra-
mine. These and related compounds have been used for
mechanistic studies of papain and other cysteine proteases
of the papain family. Although the relative lack of speci-
ficity of these compounds makes in vivo inhibition studies
difficult to interpret, in radiolabeled form they represent
powerful tools to assess inhibitor binding to a wide range
of protease targets simultaneously. 
We report the development of a new peptide epoxide MB-
074 that exploits the dipeptide Ile–Pro-OH peptide of CA-
074 to create a highly selective affinity probe for cathepsin
B. Replacing the isopropyl moiety of CA-074 with a phenol
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Figure 1
Structures of various electrophilic substrate analogs. Compounds are
all oriented as they are expected to bind in the active site of a target
enzyme such that elements to the left of the electrophile occupy
S-substrate binding sites and elements to the right of the electrophile
occupy the S′-substrate binding sites.
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introduces a site for attachment of radioactive iodine.
Covalent binding of the labeled inhibitor allows specificity
to be assessed using simple sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS–PAGE). The previ-
ously reported E-64 analog JPM-565, which already
contains a phenol moiety, was used as a probe to monitor
several identifiable lysosomal cathepsins as well as several
yet to be identified polypeptides. The specificity and cell
permeability of CA-074 and its derivatives were addressed
using JPM-565 and other nonspecific cathepsin inhibitors.
We also show that the modification of the free carboxylic
acid of CA-074 and related compounds, although confer-
ring membrane permeability, abrogates their specific
binding to cathepsin B, making this a poor choice of sites
for modification in the development of new cell-permeable
cathepsin B inhibitors. Finally, the above reagents were
used in two model systems to test their potential as tools to
monitor the biological activity of individual cathepsins
during the process of normal cell invasion as well as the
unregulated progression of tumor metastasis. 
Results
Inhibitor synthesis
On the basis of the finding that the dipeptide isoleucine–
proline portion of CA-074 was responsible for specific
cathepsin B binding [11], we synthesized analogs in which
this specificity element is retained but the simple n-propyl
moiety adjacent to the electrophilic epoxide is modified.
Using a previously reported synthesis [13] for various
peptide epoxides, we replaced the n-propylamino group
with tyramine to make the compound MB-074 (Figure 1).
We also synthesized the isobutyl analog of CA-074, named
here CA-074b, to determine the effect of a less dramatic
change in inhibitor structure. The compound JPM-565
was synthesized as reported elsewhere [20] and could be
used directly for affinity labeling because of the tyramine
moiety. Finally, we modified the dipeptide vinyl sulfone
morpholinurea-leucyl–homophenyl–vinyl sulfone phenyl
(LHVS; Figure 1) by replacing the phenyl group adjacent
to the sulfone creating LHVS-PhOH (Figure 1), which
contained a site for label attachment. Details of the syn-
thesis and characterization of LHVS-PhOH will be the
subject of a future publication.
Theoretical docking of MB-074 to the active site cathepsin B
Theoretical energy-minimized structures were obtained
for CA-074b, MB-074, I-MB-074 (2-iodo-tyramine analog
of MB-074) and I2-MB-074 (2,6-diodo-tyramine analog)
bound to the active site of cathepsin B based on the
reported crystal structure of cathepsin B inhibited by
CA-030 [11]. Our modeling results suggest that CA-074b
is a better binder than MB-074, which is in agreement
with the experimental results described below. All the
docked ligand structures retain nearly identical backbone
atom positions to the crystal ligand (CA-030) structure
(data not shown). MB-074’s carboxy-terminal carboxylic
group maintained interactions with the protein residues
His110 and His111 in the prime side occluding loop and
the isoleucine sidechain was buried deep into the S1′
pocket (Figure 2). The main structural differences among
the various ligands arise from the interactions with the
protein in the large S2 pocket. Turk et al. [11] have sug-
gested that exploiting the interactions between the ligand
and Glu245 in the S2 site should yield increased inhibitor
selectivity. The i-butyl sidechain in CA-074b is extended
into this S2 site, whereas the tyramine sidechain of
MB-074 favors extension into the solvent (Figure 2). Simi-
larly, the tyramine in I-MB-074 and I2-MB-074 are also
solvent exposed (data not shown). This orientation
towards the solvent is mainly due to the phenol moiety of
the MB-074 and its iodinated derivatives being too large
to fit in the S2 site of cathepsin B. The favorable hydro-
gen-bond energy that would be gained by interaction
between the phenol of MB-074 and Glu245 in the S2
pocket of cathepsin B is not enough to overcome the unfa-
vorable van der Waals penalty caused by a clash between
the phenyl ring of the MB-074 derivatives and other
sidechains in the S2 pockets. Hence, this explains why
addition of a large phenyl ring (and its iodination) has little
effect on inhibitor potency compared with CA-074. 
In vitro inhibition kinetics
Inhibition rate constants were obtained for MB-074,
CA-074b and CA-074 binding to purified cathepsin B by
standard Michaelis–Menten kinetic analysis as described
in the Material and methods section (kobs/[I]; Table 1).
The cathepsin-L-like cysteine protease cruzain was also
used to determine the reactivity of these same compounds
against a homologous protease that does not have the
occluding loop thought to be important for inhibitor
binding to cathepsin B. The addition of a methyl group to
the n-propyl moiety of CA-074 resulted in an inhibitor
(CA-074b) with a potency for cathepsin B nearly identical
to that of CA-074 (Table 1). Conversion to the tyramine
analog MB-074 resulted in an active inhibitor with slightly
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Figure 2
Molecular modeling structure of MB-074 bound in the active site of
cathepsin B. Note the orientation of the tyramine phenyl ring (right) and
the free carboxylate of proline complexed with the occluding loop (left).
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lower (less than tenfold reduced) activity than CA-074 and
CA-074b towards cathepsin B. This reduced activity was
presumably due to loss of binding interactions of the
inhibitor in the S2-binding pocket of cathepsin B, consis-
tent with the results from the modeling experiment
described above. All three compounds showed only weak
activity against the cathepsin-L-like cysteine protease
cruzain as reflected in high IC50 values, which could not
be accurately measured without inhibitor concentrations
causing solubility problems. These data suggest that
modifications to the n-propyl portion of CA-074 had little
effect on specificity and binding in vitro and suggests this
to be an appropriate site for chemical modification.
Specificity of inhibitors
Competition experiments were performed in a total cellu-
lar extract using the labeled, cysteine protease inhibitor
125I-JPM-565 to better define the molecular targets of
CA-074, its related family members and the reported
cathepsin S specific compound LHVS [21–23]. Lysates
from the dendritic cell line DC2.4 were prepared at acidic
pH (pH 5.5) and incubated with increasing concentrations
of E-64, LHVS, CA-074, CA-074b or MB-074. After pre-
incubation with inhibitors, radiolabeled JPM-565 was
added and the samples were analyzed by SDS–PAGE.
Pretreatment of dendritic lysates with increasing concen-
trations of E-64, as expected, resulted in a complete loss of
labeling, indicating that the two compounds share
common targets and both are capable of acting as sub-
strates for multiple cathepsins (Figure 3a). LHVS, a com-
pound reported to be selective for cathepsin S at low
concentrations, competed for binding to both cathepsin B
and S at relatively similar concentrations. LHVS also mod-
ified two minor, unidentified polypeptides at ~20 and
40 kDa and at high concentrations showed partial modifi-
cation of the major polypeptide at 33 kDa (Figure 3b). In
contrast, CA-074, bound only cathepsin B at concentra-
tions as high as 100 µM (Figure 3c). The closely related
compound CA-074b showed identical inhibition kinetics
to CA-074 for cathepsin B but at higher concentrations
bound to an unidentified 33 kDa polypeptide, which was
a major target of 125I-JPM-565 (Figure 3d). In agreement
with the observed in vitro inhibition kinetics, MB-074
showed an ~ tenfold reduction in the concentration at
which saturation of cathepsin B binding occurred when
compared with CA-074 and CA-074b. Unlike the more
closely structurally related CA-074b, however, MB-074
retained unique specificity for cathepsin B (Figure 3e).
Thus, although the Ile–Pro-OH peptide portion of
CA-074 is to a large extent responsible for the inhibitor’s
preference for cathepsin B, modifications at distal sites can
interfere with this specificity. 
MB-074 is a specific affinity label of cathepsin B
Although the competition data described above are perti-
nent to the selectivity of inhibitors for a given set of
enzymes in a complex mixture of proteins, they fail to
provide information about additional potential targets not
visualized by 125I-JPM-565 modification. A more compre-
hensive analysis of cellular targets of MB-074 was obtained
by covalent attachment of radioactive iodine to the phenol
ring of MB-074, followed by incubation with total cellular
extracts from various cell types. Incubation of lysates from
the dendritic cell line DC2.4 with labeled forms of the
peptide diazomethyl ketone Z-YA-CHN2, the peptide vinyl
sulfone LHVS-PhOH and the peptide epoxide JPM-565 all
resulted in modification of multiple polypeptides in the
range 20–45 kDa (Figure 4a). The most predominantly
labeled species was cathepsin B, which, because of its het-
erogeneous glycosylation, appeared as a diffuse band on
SDS–PAGE at ~30 kDa. The radio-iodinated form of
MB-074 showed modification of only the cathepsin B band.
To determine whether this apparently unique specificity of
MB-074 could be observed in other cell lines, we examined
the labeling using the same four electrophiles in lysates pre-
pared from the human pro-monocytic cell line U937 and
primary cytotrophoblasts isolated from human placenta
(Figure 4b,c). Labeling profiles in these cells were similar
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Table 1
Kinetic constants for inhibition of cathepsin B and cruzain by CA-074, CA-074b and MB-074.
Kobs/[I] (1/M ×1/s) IC50 (nM)
Compound Structure Cathepsin B Cruzain Cathepsin B
CA-074 15,800 ± 3750 >>10,000 40
CA-074b 29,000 ± 1000 >>10,000 60
MB-074 2750 ±450 >>10,000 400
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to those observed for the dendritic cells except that the
levels of cathepsin B activity were reduced, making it easier
to distinguish bands around 30 kDa. In both of these cell
types, 125I-MB-074 labeled what appeared to be the single
polypeptide band corresponding to cathepsin B. 
To more carefully characterize the polypeptides modified
by the above affinity reagents, lysates were incubated with
various radio-iodinated inhibitors and separated using two-
dimensional nonequilibrium pH gradient SDS–PAGE
(NEPHGE; Figure 4d). As observed in the one-dimen-
sional SDS–PAGE gels, 125I-JPM-565 modified multiple
polypeptides, some of which had identical molecular
weights to cathepsin B and were therefore not visible in
the one-dimensional SDS–PAGE profiles. As expected,
125I-JPM-565 labeled polypeptides, including cathepsin B
and cathepsin S (Figure 4d; identified by experiments
described below). Yet, only the single 30 kDa diffuse
cathepsin B spot was observed upon labeling with
125I-MB-074, demonstrating the unique specificity of this
compound for cathepsin B.
Cathepsin knock-outs reveal the identity of labeled
polypeptides
To confirm the identity of the predominant polypeptides
modified with either MB-074 or JPM-565, we examined
the labeling profiles of primary spleenocyte lysates
obtained from mice in which the cathepsin B, S or L genes
had been deleted (Figure 5). As expected, 125I-MB-074
modified the 30 kDa polypeptide (described above) in
wild-type, cathepsin S and cathepsin L knock-out spleen
cells. Labeling of the cathepsin B knock-out cells,
however, resulted in complete loss of labeling of the
30 kDa polypeptide, identifying it as cathepsin B and as
the sole target of 125I-MB-074 (Figure 4a). The same
knock-out cells could also be used to determine whether
any of the additional polypeptide species modified by the
nonspecific inhibitor JPM-565 could be identified as
cathepsin L or S. As observed previously, labeling wild-
type spleen lysates resulted in the modification of 20, 25,
30, 33 and 40 kDa polypeptides. Analysis of cathepsin B–/–
lysates modified with 125I-JPM-565 again identified the
30 kDa polypeptide as cathepsin B. Labeling of
cathepsin S–/– lysates identified the 25 kDa polypeptide as
cathepsin S, consistent with the known molecular weight
of this protease. Labeling of cathepsin L–/– cells resulted
in a pattern of polypeptides identical to that obtained for
wild-type cells, indicating that none of the species modi-
fied by 125I-JPM-565 represented cathepsin L. 
CA-074b and MB-074 have no effect on cathepsin B in vivo
We next set out to address whether CA-074 and its deriva-
tives were cell permeable and therefore could be used for
in vivo studies as previously reported. Addition of either
CA-074b or MB-074 to intact mouse dendritic cells
(DC2.4) at concentrations as high as 100 µM resulted in no
appreciable block of 125I-LHVS labeling of any polypep-
tides, including cathepsin B (Figure 6a). As competition
studies performed with both of these compounds showed
dose-dependent activity in lysates, these data suggest that
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Figure 3
CA-074 and MB-074 but not CA-074b are
highly specific for cathepsin B in total cellular
extracts. Lysates prepared from the dendritic
cell line DC2.4 were treated with increasing
concentrations (as indicated) of (a) E-64,
(b) LHVS, (c) CA-074, (d) CA-074b or
(e) MB-074 prior to addition of 125I-JPM-565
and analysis by SDS–PAGE as described in
the Materials and methods section. Lanes
labeled 0 show the pattern of multiple
polypeptides modified by the E-64 analog
125I-JPM-565 in the absence of inhibitors. The
position of inhibitor-labeled cathepsin B
(Cat B) and cathepsin S (Cat S) are
indicated. Predominant labeled polypeptides
that could not be identified are indicated by
their apparent molecular weight as judged by
proximity to size standards.
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neither compound was capable of entering the lysosome
and inhibiting their target. CA-074 treatment of mice has
been reported to result in both resistance to Leishmania
major infection and a switch from a Th2 to a Th1 immune
response upon infection [15]. We wanted to determine
whether these reported effects could be directly correlated
with cathepsin B modification and therefore inhibition.
Mice were treated for 2 days by interperitoneal injections
every 12 hours with either CA-074b or a control vehicle
every 12 hours as reported [15]. Spleens were then
removed and intact spleenocytes were labeled with
125I-LHVS (Figure 6b). Inhibitor treatment had no effect
on cathepsin B labeling, consistent with the cell culture
studies described above. Thus, although in vivo treatment
of mice may result in effects on antigen presentation,
these effects are not likely to be due to inhibition of
cathepsin B as had been suggested previously [14–16].
Esterification of CA-074b and MB-074 leads to dramatically
reduced potency and specificity for cathepsin B
The lack of cell permeability of CA-074 and its derivatives
prompted us to examine the effects of modification to the
charged carboxylic acid portion of this class of inhibitors.
It has been reported that esterification of the proline acid
moiety of CA-074 leads to a dramatic increase in cell per-
meability [17]. Still other reports focused on the effects of
similar types of modification on specificity for cathepsin B
[19]. The radio-labeled inhibitor 125I-JPM-565 was used to
determine the effects of methyl esterification on perme-
ability and selectivity of CA-074b and MB-074. Pretreat-
ment of intact dendritic cells with the methyl ester version
of CA-074b and MB-074 followed by labeling of the cells
with 125I-LHVS showed that complete modification of
cathepsin B required a > 50 times higher concentration of
both compounds as compared with the parent compounds
applied to DC2.4 cell lysates (compare Figure 7a with
Figure 3d,e). In addition to the reduced potency towards
cathepsin B, esterification of MB-074 and CA-074b led to
a complete loss of specificity for cathepsin B. Both ester
derivatives competed for labeling of cathepsin S and
several unidentified polypeptides, including the same
20 kDa band observed above as a target for 125I-LHVS. To
further address the loss of specificity upon modification of
the proline free acid of the CA-074 derivatives, MB-074
was iodinated and its targets identified by direct affinity
labeling of intact dendritic cells (Figure 7b). As expected
from the competition results, the ester derivative of
MB-074 was able to penetrate intact cells and covalently
modified multiple polypeptides. The profile of polypep-
tides modified by 125I-MB-074-OMe was nearly identical
to the profile of bands that were modified by the unla-
beled MB-074-OMe in competition studies. These results
suggest that if methyl ester derivatives are converted to
free-acid forms once inside the cell, the process of conver-
sion is slower than the rate of target modification. This
class of pro-drugs is therefore unlikely to be of use as spe-
cific reagents for the study of cathepsin B function in vivo. 
The inhibitor JPM-565, like the CA-074 derivatives, con-
tains a charged free carboxylic acid moiety and is a rela-
tively poor reagent for use in intact cells. The precursor
ethyl ester form of JPM-565 (JPM-565-OEt) was iodinated
and used to label intact dendritic cells (DC2.4). The ester
form of JPM-565 showed a dramatic increase in labeling
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Figure 4
The radio-iodinated form of MB-074
selectively labels cathepsin B in total extracts
from multiple cell lines. Total lysates from the
mouse dendritic cell line DC2.4 (a), the
human pro-monocyte cell line U937 (b) or
primary human cytotrophoblast isolated from
placenta (c) were labeled by addition of
125I-Z-YA-CHN2 (lane 1), 125I-LHVS-PhOH
(lane 2), 125I-JPM-565 (lane 3), or
125I-MB-074 (lane 4) and analyzed by
SDS–PAGE and autoradiography.
(d) Samples of total DC2.4 lysates labeled
with either 125I-JPM-565 (top panel) or
125I-MB-074 (bottom panel) described in (a)
were quenched with NEPHGE sample buffer
and then analyzed by two-dimensional
NEPHGE and autoradiography. The positions
of cathepsin B and S are noted based on
known molecular weights, pI’s and results
described in Figure 5. Unidentified
polypeptides are indicated by their
approximate molecular weight as judged by
standards.
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intensity of the same polypeptides modified by the parent
JPM-565, indicating an increase in cell permeability
(Figure 7b). Several additional polypeptides near 55 kDa
that were not modified by JPM-565 were intensely
labeled by JPM-565-OEt. Esterification of inhibitors such
as JPM-565 can therefore render some otherwise ineffec-
tive compounds useful for in vivo studies.
Affinity labels reveal cathepsin activity during invasion
processes
The compound 125I-JPM-565 was used to examine directly
the levels of cathepsin activity in homogenates obtained
from normal, primary tumor and metastatic tumor tissue
from several human subjects. Homogenates were incubated
with 125I-JPM-565 and then analyzed using SDS–PAGE
(Figure 8). In samples from all three patients an increase in
cathepsin B labeling was observed in metastatic tissue when
compared with normal or primary tumor samples. Further-
more, the extent of increase in cathepsin B labeling for
metastatic samples relative to normal tissue was slightly dif-
ferent for each patient. These data fit well with the reported
findings for cathepsin B’s involvement in tumor progression
and invasion [4]. Interestingly, cathepsin S labeling
decreased in tumor samples, whereas an unknown polypep-
tide at 40 kDa was modified to a varying extent. These
results suggest that although cathepsin B increases in most
metastatic tissue, the levels of activity may differ amongst
individual patients as well as tumors.
Levels of cathepsin activity were also monitored in an
in vitro differentiation model for primary cytotrophoblasts
derived from human placenta. During human placental
development, specialized epithelial cells termed cytotro-
phoblasts invade the uterus, anchoring the conceptus to
the decidua, tapping a supply of maternal blood. This
unusual behavior requires cytotrophoblasts to assume
highly specialized characteristics; some are commonly
associated with tumor cells, whereas others are typical of
endothelia. Unlike tumor invasion, however, trophoblast
invasion is precisely regulated, confined spatially to the
uterus and temporally to early pregnancy. Plating purified
cytotrophoblast stem cells on the extracellular matrix
(ECM) substrate Matrigel allows them to spontaneously
differentiate along the invasive pathway, modulating their
expression of stage-specific antigens in a manner analo-
gous to that observed during uterine invasion in situ
(reviewed in [24]). With regard to the cells’ tumor-like
properties, both adhesion molecule switching and matrix
metalloproteinase-9 (MMP-9) activation have been shown
to facilitate invasion [25–27]. However, little is known
about the role of the lysosomal cathepsins in this pathway.
Cytotrophoblasts were incubated for various times after
matrix attachment, collected and then lysed. Lysates were
labeled with either 125I-JPM-565 or the cathepsin-B-spe-
cific 125I-MB-074 and labeled bands were visualized using
SDS–PAGE followed by autoradiography (Figure 9).
Labeling of samples with 125I-MB-074 revealed only a
single polypeptide corresponding to cathepsin B. Upon
exposure of cells to the Matrigel, cathepsin B labeling
increased in a time-dependent fashion, suggesting that
activation of cathepsin B is regulated during the differen-
tiation pathway towards an invasive phenotype in these
cells. Labeling with the nonspecific 125I-JPM-565 con-
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Figure 6
The CA-074 analogs CA-074b and MB-074 show no activity in vivo.
(a) Intact spleen cells were incubated with increasing concentrations
of CA-074b and MB-074 as indicated and cathepsins visualized by
labeling with 125I-LHVS-PhOH followed by SDS–PAGE and
autoradiography. (b) CA-074b (lanes labeled (+)) or control DMSO
(lanes labeled (–)) was administered to mice by interperitoneal
injections every 6 h for 48 h. Spleens were removed and isolated intact
spleenocytes labeled with 125I-LHVS-PhOH. Cathepsin B and S were
identified based on migration in the gel as described above.
Figure 5
Cathepsin knock-out cells identify cathepsin B as the sole target of
125I-MB-074. Total lysates were obtained from spleenocytes of wild-
type mice or mice in which the cathepsin B, S or L gene had been
deleted. Lysates were labeled by addition of (a) 125I-MB-074 or
(b) 125I-JPM-565 and analyzed using SDS–PAGE and autoradiography.
The position of cathepsin B and S in the profiles was determined by the
loss of labeling in the corresponding knock-out samples and is
indicated along with several unidentified polypeptides (b).
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firmed the increase in cathepsin B activity after contact
with the synthetic matrix. Cathepsin S, a target of
JPM-565, was also activated in concert with cathepsin B
activity, whereas another unidentified 33 kDa band
showed no change in labeling throughout the 42 hour time
course. These results suggest that the activities of a subset
of cathepsins change upon differentiation of human
cytotrophoblasts. Such modulation of cathepsin activity
may be required for activation of this pathway.
Discussion
The studies reported here describe new reagents for study-
ing cathepsin biology. Chemical modification of commonly
used small-molecule protease inhibitors allows direct visual-
ization of protease activity using SDS–PAGE. These
reagents offer advantages over currently used techniques of
in-gel zymograms and fluorogenic substrate hydrolysis
assays because the target is modified within a native cellular
environment. Furthermore, as individual protein species
can be resolved using SDS–PAGE, highly specific reagents
are not required in studies of closely related proteases.
These affinity-labeling reagents are also particularly well
suited to address the specificity of other commonly used
protease inhibitors, both in vitro and in vivo. 
Often small-molecule inhibitors are used to make conclu-
sions about the role of a particular enzyme in a biological
process without knowing all potential targets for inhibition
by the reagent or to what extent inhibition of the desired
target has been achieved. In the case of CA-074, a com-
pound reported to be a selective inhibitor of cathepsin B,
specificity has been addressed using in vitro kinetic studies
with several well-characterized proteases [9,10]. Although
this method provides some information about selectivity, it
leaves open for question results obtained in crude extracts
or intact cells where the composition of possible targets
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Figure 7
The methyl esters CA-074b-OMe and
MB-074-OMe target multiple polypeptides in
DC2.4 cells. (a) DC2.4 cells were pre-
incubated with increasing concentrations of
CA-074b-OMe and MB-074-OMe as
indicated, then labeled by addition of
125I-LHVS-PhOH and samples analyzed using
SDS–PAGE and autoradiography. (b) DC2.4
cells were directly labeled by addition of
125I-JPM-565, 125I-JPM-565-OEt,
125I-MB-074, and 125I-MB-074-OMe and
labeled polypeptides visualized by
SDS–PAGE and autoradiography. 
Figure 8
Cathepsin activity in human tumor tissue
extracts. Extracts were prepared from tissue
samples of normal (N), primary tumor (P), and
metastatic tumor (M) obtained for multiple
patients (arbitrarily assigned 1, 2 and 3). The
matched sets of samples were normalized with
respect to total protein and cathepsins labeled
by addition of 125I-JPM-565 as described in
the methods section. Cathepsin B was
identified by labeling with the cathepsin B
specific probe 125I-MB-074 (data not shown).
Cathepsin S was identified by its migration
profile with respect to cathepsin B.
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present is unknown. We show here, through both indirect
and direct labeling experiments, that cathepsin B is the
sole identifiable target of CA-074 and MB-074. 
We also found that, although the important specificity
element of CA-074 is thought to be the free-acid-contain-
ing Ile–Pro dipeptide, chemical modification at the distal
side of the molecule can have a dramatic effect on speci-
ficity (Figure 3d). Addition of a phenol moiety to the pre-
existing n-propyl group of CA-074 resulted in a compound
(MB-074) that retained specificity for cathepsin B with only
a slight loss in potency. Surprisingly, addition of a simple
methyl group converting the n-propyl group of CA-074 to
an i-butyl group (CA-074b) resulted in a compound that
was equipotent to CA-074 towards cathepsin B but showed
activity against an unidentified polypeptide at 33 kDa,
potentially a member of the cathepsin protease family.
These data suggest that although the Ile–Pro dipeptide
contributes some degree of specificity to an inhibitor
towards the dipeptidyl peptidase activity of cathepsin B,
this is clearly not the only important specificity element. In
fact, small changes in the structure of CA-074 have detri-
mental effects on specificity, whereas other larger changes
to the structure have no effect whatsoever. 
In vitro kinetic data for these inhibitors obtained for puri-
fied cathepsins show that the three closely related
inhibitors MB-074, CA-074 and CA-074b are highly selec-
tive for cathepsin B over the cathepsin-L-like protease
cruzain (Table 1). One would therefore conclude that all
three would be of use in studying cathepsin B function in
vivo. Yet without careful characterization and purification
of the 33 kDa polypeptide found to be a target of CA-074b,
the loss of specificity observed upon addition of the methyl
group to CA-074 would certainly be overlooked. 
In addition to incomplete information about target speci-
ficity for many commonly used inhibitors, further confu-
sion can result from a lack of information about in vivo
inhibition efficiency for a desired target. In the case of CA-
074, in vivo effects of inhibitor treatment have been
reported [9,14,15]. We show here, however, that treatment
of either tissue culture cells or mice with CA-074 analogs
has no effect on cathepsin B labeling by 125I-LHVS-PhOH.
This class of reagents is cell impermeable and therefore
not likely to be of use for in vivo studies of cathepsin B.
To circumvent problems of permeability for the CA-074
family of inhibitors, studies have focused on the effects of
modification of the charged carboxy-terminal proline car-
boxylate [17,19]. Simple methyl esterification of this acid
group results in cell-permeable ‘pro-inhibitors’ that, once
inside the cell, are thought to be processed to the highly
selective free-acid form, CA-074 [17]. Our initial concerns
about the use of a pro-drug form of CA-074 were that
these esters would be reactive towards other cathepsins,
and that the rate of inhibition would be faster than the
rate of ester hydrolysis. Treatment of cells with the pro-
inhibitor, over time, would therefore lead to a steady state
in which multiple cathepsin activities had been blocked.
In fact, we found that this was the case, as treatment of
cells with methyl ester derivatives of both CA-074b and
MB-074, for times reported to be sufficient for ester
hydrolysis, lead to a block in labeling of multiple cathep-
sin species. This suggests that to make cell-permeable,
specific inhibitors it will be necessary to modify the
n-propyl portion of the molecule such that it imparts cell
permeability to the compound without disrupting the
dipeptide free-acid portion of the molecule. Perhaps the
use of short membrane-targeting sequences in place of the
i-propyl group will render the modified peptide cell per-
meable without loss of specificity for cathepsin B. Several
studies have focused on the specific delivery of protease
inhibitors to the lysosome by conjugation with protein
ligands such as monoclonal antibodies or transferrin
[28,29]. Such targeting strategies might be well suited to
effective delivery of the otherwise impermeable CA-074.
Radiolabeled forms of the cysteine protease inhibitors
Z-Tyr–Ala–CHN2 and Fmoc-Tyr–Ala–CHN2 have previ-
ously been used to study cathepsins in living cells. Shaw,
Mason and coworkers [30,31] were able to approximate con-
centrations of cathepsin B and L in various cell lines, includ-
ing several tumor-derived cell lines. They found that levels
of cathepsin B and L protease activity correlate with inva-
siveness of tumors. These studies have shown, however,
that it is difficult to quantitate levels of cathepsin B and L
activity, mainly because cathepsin B and L comigrate in
SDS–PAGE gels and because of the inconsistency of
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Figure 9
Activity of cathepsin B and cathepsin S is up-regulated during initiation of
the invasive phenotype in primary human cytotrophoblasts. Primary
human cytotrophoblasts were isolated from placenta tissue and plated on
the synthetic matrix, Matrigel. Cells were harvested from the matrix after
various times of incubation as indicted. Total cellular extract obtained
from these time points were incubated with either (a) 125I-MB-074 or
(b) 125I-JPM-565. Labeled polypeptides were visualized by SDS–PAGE
and autoradiography. The identity of cathepsin B was determined by
125I-MB-074 labeling. The identity of cathepsin S was determined by its
migration relative to cathepsin B as observed in previous experiments.
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protein recovery using immunoprecipitation. Our results
described here for inhibitor labeling of primary human
tissues agree with these reported findings, as well as with
studies reporting cathepsin expression in tumors. In addi-
tion, introducing 125I-MB-074 as a cathepsin-B-specific label
will allow cathepsin B activity to be directly monitored
without concern for contributions from overlapping pro-
teases, a problem associated with the less specific labels.
The process by which placental cytotrophoblasts invade
the uterine wall and establish connections with maternal
blood has been considered to be similar to invasion mecha-
nisms used by tumor cells during metastasis [24]. Studies
have focused on the expression of cell-adhesion markers
and matrix metalloproteases in in vitro invasion models
established using purified primary cells [25,26,32]. Our
results indicate that cathepsin activity is stimulated when
primary cytotrophoblasts are induced to undergo the differ-
entiation cascade leading to the invasive phenotype
(Figure 9). Cathepsin B and S activity, in particular, are dra-
matically up-regulated after exposure of cells to Matrigel.
Although these findings are only preliminary, they demon-
strate the use of labeled inhibitors to follow protease activ-
ity in total extracts. Work is already underway to establish
the role these enzyme may play in the invasion pathway. In
particular, it is not clear whether activation of cathepsins is
a cause or effect of invasion. Answers to such questions are
likely to require specific inhibitors that can be used in vivo
coupled with the labeling techniques described here. 
Significance
The lysosomal cysteine proteases of the papain family
known as cathepsins perform many tasks within the
cell. Reduced or elevated levels of activity of these
enzymes are associated with many disease states. Tech-
niques used to specifically monitor protein levels of indi-
vidual cathepsins often fail to correlate with enzyme
activity, whereas methods for determining activity are
usually unable to provide absolute discrimination
between closely related proteases. For this reason new
reagents that allow individual protease activities to be
simply and accurately detected by chemically modifying
targets are likely to be of value for studying a wide range
of proteolytic enzymes. We show here that specific affin-
ity labels such as MB-074 and several other less specific
reagents that covalently tag their targets in the process
of inhibition provide information about the lysosomal
cysteine proteases that would otherwise be difficult or
impossible to obtain. Specifically, these reagents show
that cathepsins may be differentially expressed in differ-
ent tumor types and in individual patients. Moreover,
using these types of compounds as activity-dependent
diagnostics could provide a simple method for profiling
of cathepsin activity upon biopsy of tumor tissue, provid-
ing information that may be of use for determining an
effective route for chemotherapeutic intervention. These
studies also show that activity of specific cathepsins is
regulated during the process by which cells of the pla-
centa begin to invade the maternal host tissue, establish-
ing blood flow to a developing fetus. Although these
studies provide solid examples of the uses for active-site-
directed affinity labels, diversification of these reagents
is likely to generate additional tools that have great
potential for use in studying virtually any process or
disease state where proteases are suspected to play an
important role. 
Materials and methods
Reagents
Morpholineurea-leucinyl-homophenalanyl-vinylsulfone-phenyl (LHVS)
and JPM-565 were kind gifts of Hidde Ploegh (Harvard Medical
School, Boston, MA). Z-YA-CHN2 was purchased from Enzyme
Systems Products (Dublin, CA). E-64 was purchased from Peptides
International (Louisville, KY). CA-074 was a kind gift of James McKer-
row (University of California, San Francisco, San Francisco, CA). 
Inhibitor synthesis
Synthesis of inhibitors that have not been previously reported are
described below. All inhibitors were dissolved in dimethylsulfoxide
(DMSO) unless otherwise noted. Typically DMSO stock solutions were
prepared such that after dilution, the final working concentration of
DMSO did not exceed 1%.
Synthesis of phenolic containing peptide vinyl sulfones
The phenolic vinyl sulfone LHVS-PhOH was synthesized using proto-
cols previously described for several vinyl sulfone inhibitors of the pro-
teasome [33]. Briefly, Boc-homophenylalanine was converted to the
corresponding Weinreb Amide, reduced with lithium aluminum hydride
to yield Boc-homophenylalanal, which was then converted to the corre-
sponding phenolic vinyl sulfone by reaction with a phosphorous ylide
using standard Wittig chemistry. Subsequent removal of the Boc group
and coupling to the morpholine urea capped leucine yielded the target
compound LHVS-PhOH in good yield. The synthetic details and further
applications of this compound will be the focus of a future publication.
Synthesis of CA-074 analogs
Peptide epoxides related to published cathepsin B inhibitor CA-074
were synthesized essentially as described [13,19] (Figure 10). Syn-
thetic details are included in the Supplementary material.
Covalent docking of ligands to the active site of cathepsin B
The 2.0 Å resolution of human cathepsin B crystal structure complexed
with CA-030 (pdb identifier: 1CSB) [11] was used in the docking
study. Structures of CA-074b, MB-074, I-MB-074, and I2-MB-074
were generated from the crystal template of CA-030 using the SYBYL
program from Tripos [34]. Amber 95 [35] charges were applied to the
protein and Gasteiger–Marsilli charges [36] were calculated for the
ligands. Using a modified DOCK4.0 [37] algorithm, a covalent bond
was placed between the sulfur atom of Cys29 of the protein and the
C2 carbon atom (numbering according to Turk et al. [11]) of the
ligands. The harmonic bond and angle parameters obtained from
parm95 [35] of AMBER were applied to the S-C2 bond and CA-S-C2
angle. The ligands were allowed to grow flexibly from the anchor site of
‘S-C2’. The resultant top non-bonded force field docked ligand struc-
tures were then re-scored using a generalized-Born model to account
for the solvation [38].
In vivo treatment with CA-074b
Female Balb/c mice were injected interperitoneal with CA-074b
(0.25 mg in 500 µl saline) or vehicle (DMSO, 5 µl in 500 µl saline)
every 12 h for 2 days as described in [15]. After completion of the
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injection time-course spleens were removed and spleenocytes isolated
as described below.
Cell isolation and culture
Cytotrophoblasts were isolated from pools of first trimester placentas
by published methods [25]. In all cases, remaining leukocytes were
removed using an antibody to CD-45, a protein tyrosine phosphatase
found on bone-marrow-derived cells [39] coupled to magnetic beads.
The resulting cells were plated on Matrigel-coated substrates (Collabo-
rative Biomedical Research, Bedford, MA) and cultured in DME H21
minimal essential medium containing 2% Nutridoma (Boehringer
Mannheim, Indianapolis, IN) and 50 µg/ml gentamicin [25] under stan-
dard tissue culture conditions (5% CO2/95% air). 
Primary mouse spleenocytes were obtained from normal, cathepsin B,
cathepsin L and cathepsin S deficient mice (kind gift of Hidde Ploegh,
Harvard Medical School, Boston, MA) by physical disruption of an intact
spleen submerged in RPMI media supplemented with 10% fetal calf
serum. Large tissue matter was removed by filtering through a sterile
mesh and cells isolated by centrifugation. Red blood cells were removed
by lysis in a hypotonic solution (0.17 M ammonium chloride) followed by
centrifugation and washing of the remaining spleenocytes with PBS.
The dendritic cell line DC2.4 was generated by Kenneth Rock and was
obtained from the Dana-Farber Cancer Institute (Boston, MA) under
transfer agreement. All cell lines (U937, DC2.4) were maintained in
RPMI medium supplemented with 10% fetal calf serum using standard
tissue culture protocols. 
Kinetic assays
Simple IC50 values were determined by pre-treatment of recombinant
cruzain lacking the carboxy-terminal domain (4 nM; kind gift of James
McKerrow) or cathepsin B (4 nM; Sigma, St. Louis, MO) in 100 assay
buffer (100 mM sodium acetate pH 5.5, 10 mM DTT) with each of the
three inhibitors CA-074, CA-074b, and MB-074 over a 10–10000 nM
range for 5 min at room temperature. The substrate Z-FR-MCA (100 µM;
Bachem, King of Prussia, PA) was then added and progress curves
monitored for 10 min. Slopes of each linear curve were determined by
linear least squares fitting and recorded as a ratio of uninhibited versus
inhibited reaction rates. IC50 values were approximated by extrapolation
from plots of concentration vs % residual activity to determine inhibitor
concentrations that resulted in 50% inhibition of hydrolysis activity. 
Values of kobs/[I] were obtained as follows. Inhibitor dilutions that
resulted in simple progress curves over a wide range of kobs were used
to determine kinetic parameters. Progress curves of Z-FR-MCA (20 µM
for cruzain; 100 µM for cathepsin B) hydrolysis in the presence of
inhibitor were measured for 10 min. Values for kobs, the pseudo-first
order rate constant for inactivation of enzyme, were obtained for the
equation:
Fluorescence = vst + [(vo–vs)/kobs][1–exp(–kobst)]
for pseudo-first order dynamics using UltraFit (Biosoft). Kinetic data is
displayed as averages of multiple inhibitor concentrations performed in
duplicate for kobs/[I] where [I] is the concentration of inhibitor used to
obtain each progress curve.
Radiolabeling of inhibitors
All compounds were iodinated and isolated using the reported protocol
[31,40]. Briefly, a glass test tube was coated with 100 µg of Iodo-gen
(Pierce, Rockford, IL). The tube was placed on ice and inhibitor (25 µl
of a 5 mM solution in ethanol/phosphate buffer pH 7.5 (v:v)) was
added to the tube. Finally, 1 mCi of Na125I (10 µl) was added to the
tube and incubation continued on ice for 15 min. The labeled inhibitor
was purified by application to a sep-pak (Waters, Milford, MA) column
containing a C18 stationary phase. After the sample was applied to the
column, the column was washed with 30 ml of phosphate buffer
pH 7.5. Labeled inhibitor was then eluted using 100% acetonitrile.
Fractions of 1 ml were collected and the fractions with the greatest
number of counts were pooled. 
Preparation of total cellular lysates from DC2.4, U937, primary
spleen cells, cytotrophoblasts and primary human tissue 
Cells were lysed using a bead smashing technique described previously
[33]. Briefly, cells were washed 3× with cold PBS and then collected by
centrifugation. A volume of glass beads (< 106 microns, acid washed;
Sigma Chem. Co., St. Louis, MO) equivalent to the volume of the pellet
were added followed by a similar volume of homogenization buffer
(50 mM Tris pH 5.5, 1 mM DTT, 5 mM MgCl2, 250 mM sucrose). Cells
were vortexed at high speed for 1 min. The beads and broken cell debris
were removed by centrifugation at 10,000 g for 5 min. The resultant
homogenate was centrifuged at 10,000 g for 20 min to remove unbroken
cells and nuclei. Protein concentration was determined using the BCA
protocol described by the manufacturer (Pierce Chem. Co., Rockford, IL).
Frozen tissue pieces from time-matched colon cancer sets, or individ-
ual tumors (tumor, nearby normal tissue, and liver metastasizes stored
at –70°C), were homogenized in 250 µl/ mg ice cold PBS with 0.1%
Triton × 100 using a Tenbrock homogenizer on ice. The homogenate
was centrifuged in a 4°C microfuge at 16 K g for 10 min. High salt
extracts were prepared by resuspending these pellets at 10 µl/mg in
50 mM Na acetate pH 6.1, 2 M NaCl , vortexing for 3 min and collect-
ing the supernatants as above. Pellets and supernatants were stored at
–70°C. Protein levels were determined for each sample by quantitation
using the BCA method. Equal amounts of total protein were used for all
labeling experiments.
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Figure 10
Synthesis of the peptide epoxides CA-074b-OMe, MB-074-OMe,
CA-074b and MB-074.
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Labeling of lysates and intact cells with iodinated inhibitors
Equivalent amounts of radioactive inhibitor stock solutions (~ 106 cpm
per sample) were used for all labeling experiments. It should be noted,
however, that not all inhibitors may have been modified to the same
extent during iodination [40]. It is difficult to determine the amount of
unlabeled inhibitor present in a given labeling stock so these reagents
should not be used as quantitative measures of inhibitory or protease
activity. Relative inhibition of radiolabeling of specific proteases by cold
competition can be used to make quantitative observations. Samples of
lysates (50 µg total protein in 50 µl buffer; 50 mM tris pH 5.5, 5 mM
MgCl2, 2 mM DTT) were labeled for 2 h on ice unless noted otherwise
and were quenched by dilution of 4× SDS sample buffer to 1× (for one-
dimensional SDS–PAGE) or by dissolving urea to a final concentration
of 9.5 M (for two-dimensional SDS–PAGE).
Competition labeling experiments
Nonradioactive inhibitors (CA-074, CA-074b, MB-074, MB-074-OMe,
CA-074b-OMe, E-64 and LHVS) were added to lysates on ice (prepared
as described above) at the concentrations indicated. Samples were pre-
incubated for 1 h and then labeled by addition of the inhibitor
(125I-JPM-565, 125I-LHVS-PhOH; ~106 cpm/sample). Labeling was
quenched after 2 h on ice by addition of 4 × SDS sample buffer to a final
concentration of 1× followed by boiling and analysis by SDS–PAGE.
Gel electrophoresis
One-dimensional SDS–PAGE, two-dimensional NEPHGE were per-
formed as described previously [41]. 
Supplementary material
Supplementary material including the synthesis of MB-074 and CA-074b
is available at http://current-biology.com/supmat/supmatin.htm.
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